TGFBR2 and pancreatic neoplasm: Our study uncovered the relationship between circSEC24A and TGFBR2 in the malignant progress of pancreatic cancer, considering that TGFBR2 inhibitor was a potent drug for pancreatic cancer, therefore, we deduced that circSEC24A/miR-606/TGFBR2 signal axis might become a biomarker for diagnosis and treatment of pancreatic cancer.